Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Rheumatology · Behçet's Disease

What is the Life Expectancy with Behçet's Disease?

At a Glance

For the vast majority of patients, life expectancy with Behçet's disease is normal. While typical symptoms are painful, they are not life-threatening. Rare, severe complications in blood vessels, the brain, or the digestive tract can impact survival, but modern treatments have dramatically improved long-term outcomes.

In this answer

2 sections

01

When Can Behçet’s Disease Affect Life Expectancy?

02

The Impact of Modern Treatments

For the vast majority of people with Behçet’s disease, life expectancy is completely normal. Because the condition most commonly affects the skin, mouth, and joints, these symptoms—while painful and disruptive to daily life—are not life-threatening. With ongoing monitoring and effective symptom management, most patients live full, normal-length lives. [1][2]

However, Behçet’s disease is a systemic condition, meaning it can affect different parts of the body. In rare cases, it can involve major organs or blood vessels, which can impact long-term health and survival if not treated promptly. Fortunately, modern medical treatments have dramatically improved the outlook even for patients with severe forms of the disease. [3][4][5]

When Can Behçet’s Disease Affect Life Expectancy?

While the disease does not shorten life for most people, there are specific, rare complications that are considered medical emergencies. These severe complications are the primary drivers of mortality in Behçet’s disease: [6][7]

  • Severe Vascular Involvement: Behçet’s can cause inflammation in the blood vessels (vasculitis). In severe cases, this can lead to aneurysms (bulging or ballooning of a weakened blood vessel wall), particularly in the pulmonary artery (the artery carrying blood from the heart to the lungs) or the aorta. If an aneurysm ruptures, it is life-threatening. Blood clots (thrombosis) in deep veins or arteries are also a serious risk. [8][9][10]
    • Warning Signs to Seek Emergency Care: Sudden or severe chest pain, coughing up blood, sudden shortness of breath, or painful swelling in a leg.
  • Neurological Involvement (Neuro-Behçet’s): Inflammation can affect the brain and central nervous system. This can manifest as meningitis or blood clots in the brain’s veins (cerebral venous thrombosis). Damage to the brain tissue itself (parenchymal brain involvement) is a serious complication that requires immediate, aggressive treatment. [11][12][4]
    • Warning Signs to Seek Emergency Care: Sudden blinding headaches, unexplained confusion, personality changes, weakness in the arms or legs, or sudden mobility and balance issues.
  • Severe Gastrointestinal (GI) Involvement: Deep ulcers can form in the intestines, which may lead to severe internal bleeding or bowel perforation (a tear or hole in the intestine wall). [13]
    • Warning Signs to Seek Emergency Care: Severe abdominal pain that doesn’t go away, bloody stools, or vomiting blood.

Who is at Higher Risk?

Research indicates that the risk for severe organ involvement is not the same for everyone. Statistically, young men (especially those diagnosed before age 30) are at a higher risk for developing aggressive vascular, cardiac, and neurological complications compared to women or individuals who develop the disease later in life. [14][15][16]

This does not mean every young male will develop these issues, but it highlights the critical need for proactive monitoring. Instead of just waiting for symptoms to appear, high-risk individuals may need routine imaging (like MRIs or CT angiograms) and regular evaluations by a multidisciplinary team, including a rheumatologist, neurologist, or vascular specialist.

The Impact of Modern Treatments

The most encouraging news for anyone diagnosed with Behçet’s disease today is the revolution in modern treatments. Historically, severe organ involvement was very difficult to manage, but advanced medications have changed the landscape.

  • Corticosteroids: During an acute, potentially life-threatening flare, doctors often use high doses of glucocorticoids (like prednisone) to rapidly suppress the immune system and bring dangerous inflammation under control quickly. [17]
  • Immunosuppressants and Biologics: For long-term management, drugs that suppress or modulate the immune system, particularly TNF-alpha inhibitors (like infliximab and adalimumab), have proven highly effective. These medications target specific proteins in the immune system to reduce inflammation. They are used to treat severe eye, vascular, and neurological involvement, often putting the disease into remission and preventing irreversible organ damage. [13][18][19]
  • Early Intervention: Catching severe symptoms early and initiating aggressive therapy significantly improves survival rates and long-term prognosis. [20][21][22]

Because the landscape of treatment has improved so much, patients with even severe forms of Behçet’s disease are living longer, healthier lives than in previous decades. [4][5]

Common questions in this guide

Is Behçet's disease life-threatening?
For most people, Behçet's disease is not life-threatening and life expectancy is completely normal. However, in rare cases, severe complications involving major blood vessels, the central nervous system, or the gastrointestinal tract can become medical emergencies.
Who is at the highest risk for severe complications from Behçet's disease?
Statistically, young men who are diagnosed before the age of 30 are at a higher risk for developing aggressive vascular and neurological complications. High-risk individuals often require proactive monitoring and regular evaluations by a multidisciplinary medical team.
What are the emergency warning signs of severe Behçet's complications?
You should seek immediate medical care if you experience sudden chest pain, coughing up blood, blinding headaches, unexplained confusion, sudden balance issues, or severe, lingering abdominal pain. These symptoms could indicate dangerous inflammation in your major organs or blood vessels.
How do doctors treat severe Behçet's disease?
During an acute flare, doctors often use high doses of corticosteroids to quickly control inflammation. For long-term management, immunosuppressants and biologic medications like TNF-alpha inhibitors are highly effective at suppressing the immune system and preventing organ damage.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my age, sex, and current symptoms, am I considered high-risk for severe vascular or neurological complications?
  2. 2.Should I undergo any baseline screening tests, such as a CT angiogram of my chest or an MRI of my brain, to check for silent organ involvement?
  3. 3.What specific 'red flag' symptoms should prompt me to go to the emergency room immediately versus waiting for my next appointment?
  4. 4.If I were to experience a severe flare involving my major organs, what is our action plan, and which specialist on my care team should I contact first?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Can Behçet's Disease Cause Blindness? Vision RisksCan You Have a Healthy Pregnancy with Behçet's Disease?Does Behçet's Disease Cause Severe Fatigue & Tiredness?Will Behçet's Disease Burn Out With Age?Neuro-Behçet's vs MS: How Doctors Tell Them ApartHow Often Do You Need Eye Exams with Behçet's Disease?How to Manage Anxiety With Behçet's Disease?How to Relieve Behçet's Mouth Ulcer PainIs Behçet's Disease Contagious? What You Need to KnowIs Behçet's Disease Hereditary? HLA-B51 Gene ExplainedIs Behçet's Disease More Severe in Young Men?What Doctors Treat Behçet's Disease?What Do ESR & CRP Tests Mean in Behçet's Disease?What Is the Best Diet for Behçet's Disease?What is the Difference Between Behçet's and Crohn's?What Is the Difference Between Behçet's and Herpes?What Is the Pathergy Test for Behçet's Disease?What Triggers a Behçet's Disease Flare-Up? Key CausesWhy Avoid Blood Thinners for Behçet's Clots?

References

References (22)
  1. 1

    Vascular involvement in Behçet's disease: the immunopathological process.

    de Vargas RM, da Cruz MLN, Giarllarielli MPH, et al.

    Jornal vascular brasileiro 2021; (20()):e20200170 doi:10.1590/1677-5449.200170.

    PMID: 34267787
  2. 2

    Behçet syndrome: a contemporary view.

    Yazici H, Seyahi E, Hatemi G, Yazici Y

    Nature reviews. Rheumatology 2018; (14(2)):107-119 doi:10.1038/nrrheum.2017.208.

    PMID: 29296024
  3. 3

    Mortality associated with Behçet's disease in France assessed by multiple-cause-of-death analysis.

    David E, Fauvernier M, Saadoun D, et al.

    Clinical rheumatology 2022; (41(6)):1749-1758 doi:10.1007/s10067-021-06027-5.

    PMID: 35091777
  4. 4

    Infliximab therapy in parenchymal neuro-Behçet's disease: A single-center experience.

    Yalcin Kehribar D, Gunaydin S, Ozgen M

    International journal of rheumatic diseases 2021; (24(10)):1302-1307 doi:10.1111/1756-185X.14209.

    PMID: 34427044
  5. 5

    Pulmonary Artery Aneurysm in Behcet Disease: Medical, Endovascular or Surgical Intervention.

    Samreen I, Darji P, Genobaga S, et al.

    Cureus 2023; (15(11)):e49368 doi:10.7759/cureus.49368.

    PMID: 38146562
  6. 6

    Inferior Vena Cava Thrombosis and Pulmonary Embolism in a Patient With Behcet Disease: A Rare Presentation.

    Mushtaq MH, Ali Khan O, Khan H, et al.

    Cureus 2023; (15(8)):e44184 doi:10.7759/cureus.44184.

    PMID: 37767251
  7. 7

    Cortical Subarachnoid Hemorrhage in Behcet's Disease.

    Topcuoglu MA, Arsava EM, Balci S, Arat A

    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2022; (31(4)):106351 doi:10.1016/j.jstrokecerebrovasdis.2022.106351.

    PMID: 35152133
  8. 8

    Imaging characteristics and prognostic factors of Behcet's disease with arterial involvement: A long-term follow-up study.

    Qian YL, Quan RL, Chen XX, et al.

    European journal of radiology 2024; (170()):111206 doi:10.1016/j.ejrad.2023.111206.

    PMID: 37995514
  9. 9

    The Effectiveness of Infliximab in Treating Vascular Manifestations of Behçet's Disease: A Systematic Review and Meta-Analysis.

    Bennani A, Benmansour EK, Serraj K

    Mediterranean journal of rheumatology 2025; (36(4)):539-546 doi:10.31138/mjr.080325.tav.

    PMID: 41607598
  10. 10

    Vasculo-Behçet's disease with a giant pseudoaneurysm of superficial femoral artery: A case report.

    Al-Doud MA, Al-Nusairat AN, Al-Shanableh NM, et al.

    International journal of surgery case reports 2023; (109()):108534 doi:10.1016/j.ijscr.2023.108534.

    PMID: 37524014
  11. 11

    The Clinical Features and Risk Factors of Parenchymal Neuro-Behcet's Disease.

    Yan D, Liu J, Zhang Y, et al.

    Journal of immunology research 2019; (2019()):7371458 doi:10.1155/2019/7371458.

    PMID: 31612152
  12. 12

    Neuro-Behçet's Disease With Coma.

    Hamid M, Cherradi S, Ait Berri M, Bourazza A

    Cureus 2022; (14(11)):e31596 doi:10.7759/cureus.31596.

    PMID: 36540466
  13. 13

    Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases.

    Atienza-Mateo B, Martín-Varillas JL, Calvo-Río V, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2019; (71(12)):2081-2089 doi:10.1002/art.41026.

    PMID: 31237427
  14. 14

    Multiorgan involvement of Behçet's disease in a young woman.

    Tamer F, Gülru Erdoğan F, Dinçer Rota D, Yıldırım D

    Acta dermatovenerologica Alpina, Pannonica, et Adriatica 2018; (27(3)):153-154.

    PMID: 30244267
  15. 15

    Relationship between age at onset and clinical characteristics of Behçet's disease.

    Ghembaza MEA, Lounici A

    Acta dermatovenerologica Alpina, Pannonica, et Adriatica 2018; (27(4)):175-177.

    PMID: 30564829
  16. 16

    [Frequency and predictive factors of venous thrombosis in Behçet's disease].

    Ha-Ou-Nou FZ, Essaadouni L

    La Revue de medecine interne 2020; (41(9)):578-582 doi:10.1016/j.revmed.2020.03.010.

    PMID: 32471710
  17. 17

    Analysis of the treatment of aneurysm involved in vascular Behçet's disease (three cases).

    Zhang SH, Zhang FX, Zhang H

    Annali italiani di chirurgia 2020; (91()):397-401.

    PMID: 33162403
  18. 18

    Biotherapies in Uveitis.

    Leclercq M, Desbois AC, Domont F, et al.

    Journal of clinical medicine 2020; (9(11)) doi:10.3390/jcm9113599.

    PMID: 33171664
  19. 19

    Infliximab versus Cyclophosphamide for Severe Behçet's Syndrome.

    Saadoun D, Maalouf G, Vieira M, et al.

    NEJM evidence 2024; (3(11)):EVIDoa2300354 doi:10.1056/EVIDoa2300354.

    PMID: 39437137
  20. 20

    Pulmonary Arterial Aneurysms and Thrombosis in a Young Male: A Rare Presentation of Behcet's Disease.

    Kurada BRV, Umeh CA, Gupta RC, et al.

    Cureus 2023; (15(7)):e41928 doi:10.7759/cureus.41928.

    PMID: 37583732
  21. 21

    Disease and Treatment-Specific Complications of Behçet Syndrome.

    Esatoglu SN, Ozguler Y, Hatemi G

    Current rheumatology reports 2024; (26(1)):1-11 doi:10.1007/s11926-023-01124-7.

    PMID: 37995045
  22. 22

    Pulmonary artery thrombosis as the first presentation of Behçet's syndrome: a case report and review of the literature.

    Alakkas Z, Kazi W, Mattar M, et al.

    Journal of medical case reports 2021; (15(1)):322 doi:10.1186/s13256-021-02931-1.

    PMID: 34154640

This page explains life expectancy and complications related to Behçet's disease for educational purposes. Always discuss your specific prognosis and symptom management with your rheumatologist or healthcare team.

Get notified when new evidence is published on Behçet disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.